News

HPV Vaccine's Benefits Are Mainly Extracervical


 

EXPERT ANALYSIS FROM A CONFERENCE ON PEDIATRIC INFECTIOUS DISEASES SPONSORED BY CHILDREN'S HOSPITAL COLORADO

"We don’t know that two doses would be as good as three for the duration of a woman’s life or a man’s life, but it may be good enough. You really want to protect people when they’re most sexually active and most likely to have multiple partners. Then when they settle down, they’re less likely to be at risk, and it doesn’t matter as much if they’re not as protected," Dr. Levin explained.

He reported that he serves as a consultant to Merck and GlaxoSmithKline and holds intellectual property rights involving Merck’s Zostavax shingles vaccine.

Pages

Recommended Reading

ASCO 2012: Radium-223 and Prostate Cancer Survival
MDedge Hematology and Oncology
New Analysis Revises Benefits of PSA Screening Downward
MDedge Hematology and Oncology
Blood Test May Predict Temsirolimus Response in Kidney Cancer
MDedge Hematology and Oncology
Will They Still Give Strong to Lance Armstrong's Cancer Charity?
MDedge Hematology and Oncology
FDA Approves Enzalutamide for Prostate Cancer
MDedge Hematology and Oncology
Intermittent Androgen Suppression 'Noninferior' to Continuous in Prostate Cancer
MDedge Hematology and Oncology
The Development of an eHealth Tool Suite for Prostate Cancer Patients and Their Partners
MDedge Hematology and Oncology
FDA Approves New Imaging Agent for Prostate Cancer Detection
MDedge Hematology and Oncology
Community Oncology Podcast - Abiraterone in metastatic prostate cancer
MDedge Hematology and Oncology
Active Surveillance Favored for Low-Risk Prostate Cancer
MDedge Hematology and Oncology